Overview

Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the combination of bevacizumab and pemetrexed have an effect on recurrent ovarian and primary peritoneal carcinoma by looking at progression and survival at 6 months.
Phase:
Phase 2
Details
Lead Sponsor:
Washington University School of Medicine
Collaborator:
Columbia University
Treatments:
Bevacizumab
Pemetrexed